These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4050061)

  • 1. [Effects of prostaglandin El on hemodynamics and metabolism of the extremities in healthy humans and patients with stage III and IV arterial occlusive disease].
    Rexroth W; Amendt K; Römmele U; Stein U; Wagner E; Hild R
    Vasa; 1985; 14(3):220-4. PubMed ID: 4050061
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies of muscle metabolism in chronic major limb arterial occlusive disease patients by unilateral ergometric lower leg stress (III)].
    Nissen P; Alexander K
    Vasa; 1985; 14(4):330-5. PubMed ID: 4072367
    [No Abstract]   [Full Text] [Related]  

  • 3. [Placebo controlled, double-blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease].
    Stiegler H; Diehm C; Grom E; Martin M; Mörl H; Rudofsky G; Vogelberg KH
    Vasa Suppl; 1992; 35():164-6. PubMed ID: 1481031
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostacyclin in peripheral arterial occlusive disease (PAOD): clinical and hemodynamic findings in patients with PAOD stage III and IV.
    Valentin A; Karnik R; Sehnal E; Slany J
    Prog Clin Biol Res; 1987; 242():457-62. PubMed ID: 3313420
    [No Abstract]   [Full Text] [Related]  

  • 5. [The use of Vasaprostan (prostaglandin E1) in treating patients with obliterating arterial diseases of the lower extremities].
    Lebedev LV; Afonin DN
    Vestn Khir Im I I Grek; 1993; 150(5-6):153-7. PubMed ID: 8091569
    [No Abstract]   [Full Text] [Related]  

  • 6. [Placebo controlled study of the effect of intravenous PGE1 on macro- and microcirculation in patients with stage III/IV arterial occlusive disease].
    Scheffler P; de la Hamette D; Leipnitz G
    Vasa Suppl; 1991; 33():343-4. PubMed ID: 1788750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of hydroxyethyl starch and dextran on metabolism of extremity muscles in patients with arterial occlusive disease].
    Stark G; Tischler R; Decrinis M; Lafer M; Obernosterer A; Pieber D; Pilger E
    Vasa Suppl; 1991; 33():171. PubMed ID: 1724099
    [No Abstract]   [Full Text] [Related]  

  • 8. [Duplex ultrasound measurement of hemodynamic parameters at rest and following arterial stenosis: effect of intra-arterial infusion therapy with prostaglandin E1].
    Ranke C; Creutzig A; Alexander K
    Vasa Suppl; 1989; 27():353-5. PubMed ID: 2696104
    [No Abstract]   [Full Text] [Related]  

  • 9. [Administration of prostaglandin E1 in diabetics and non-diabetic patients with severe Fontaine stage IIb arterial occlusive disease].
    Hinderer S; Brachmann R; Nedder KH; Bucher J; Beischer W
    Vasa; 1991; 20(2):100-8. PubMed ID: 1877328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiopulmonary effects of prostaglandin E1. Aspects of drug safety].
    Heidrich H; Breddin HK; Rudofsky G; Scheffler P
    Med Klin (Munich); 1992 Mar; 87(3):123-30. PubMed ID: 1579089
    [No Abstract]   [Full Text] [Related]  

  • 11. [Double-blind placebo-controlled study of the behavior of tcPO2 during intravenous infusion of prostaglandin E1 in patients with severe arterial occlusive disease].
    Creutzig A; Caspary L; Alexander K
    Vasa Suppl; 1992; 35():36-8. PubMed ID: 1481055
    [No Abstract]   [Full Text] [Related]  

  • 12. [Intra-arterial treatment of arterial obliterative disease (author's transl)].
    Mörl H
    Dtsch Med Wochenschr; 1974 Nov; 99(45):2284-6. PubMed ID: 4448136
    [No Abstract]   [Full Text] [Related]  

  • 13. [Significance of prostaglandins in arterial occlusive diseases].
    Diehm C
    Internist (Berl); 1994 Aug; 35(8):764-70; discussion 771-2. PubMed ID: 7960555
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pilot study of the effect of intravenous prostavasin therapy of inpatients with diabetes mellitus and IIb arterial occlusive disease].
    Rosak C; Hofmann U; König P; Nitsche GB
    Vasa Suppl; 1991; 33():339-40. PubMed ID: 1788748
    [No Abstract]   [Full Text] [Related]  

  • 15. [Muscle metabolism and blood circulation under ergometric stress in arterial occlusive disease (II)].
    Nissen P; Maas U; Hundeshagen H; Alexander K
    Vasa; 1985; 14(1):31-4. PubMed ID: 3976274
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease.
    Milio G; Cospite V; Cospite M
    Minerva Cardioangiol; 2003 Jun; 51(3):311-6. PubMed ID: 12867883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous and intra-arterial prostaglandin E1 treatment in patients with stage IIb arterial occlusive disease].
    Rudofsky G
    Vasa Suppl; 1988; 23():121-5. PubMed ID: 3206330
    [No Abstract]   [Full Text] [Related]  

  • 18. [Metabolic changes in muscle and blood caused by ergometric stress in chronic arterial occlusive disease (I)].
    Nissen P; Alexander K
    Vasa; 1985; 14(1):25-30. PubMed ID: 3976273
    [No Abstract]   [Full Text] [Related]  

  • 19. [Randomized study comparing the clinical effectiveness of intravenous prostaglandin E1 and intravenous pentoxifylline in patients with Fontaine stage IIb arterial occlusive disease].
    Hepp W; von Bary S; Corovic D; Diehm C; Mühe E; Rudofsky G; Scheffler P; Trübestein G; Vogelpohl M
    Vasa Suppl; 1991; 33():348-9. PubMed ID: 1788753
    [No Abstract]   [Full Text] [Related]  

  • 20. [Reflex oximetry for evaluating blood redistribution in patients with arterial occlusive disease treated with PGE1].
    Thum J; Caspary L; Creutzig A; Alexander K
    Vasa Suppl; 1992; 35():39-41. PubMed ID: 1481056
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.